| GO ID | GO name | Interaction type | Reference |
|---|---|---|---|
| GO:0004022 | Alcohol dehydrogenase (nad+) activity | Decreases phenotype | PMID:33405312 |
| GO:0004602 | Glutathione peroxidase activity | Increases phenotype | PMID:18493934 |
| GO:0004784 | Superoxide dismutase activity | Increases phenotype | PMID:18493934 |
| GO:0006007 | Glucose catabolic process | Increases phenotype | PMID:31629899 |
| GO:0006085 | Acetyl-coa biosynthetic process | Increases phenotype | PMID:31654802 |
| GO:0006089 | Lactate metabolic process | Affects phenotype | PMID:39922521 |
| GO:0006611 | Protein export from nucleus | Affects phenotype | PMID:33405312 |
| GO:0006749 | Glutathione metabolic process | Affects phenotype | PMID:33259821 |
| GO:0006750 | Glutathione biosynthetic process | Decreases phenotype | PMID:18493934 |
| GO:0006754 | Atp biosynthetic process | Increases phenotype | PMID:31629899 |
| GO:0006879 | Cellular iron ion homeostasis | Affects phenotype | PMID:33259821 |
| GO:0008152 | Metabolic process | Affects phenotype | PMID:28962523 |
| GO:0008219 | Cell death | Increases phenotype | PMID:26343699; PMID:33259821 |
| GO:0008283 | Cell population proliferation | Decreases phenotype | PMID:25630799; PMID:28962523 |
| GO:0009060 | Aerobic respiration | Decreases phenotype | PMID:29653124 |
| GO:0010918 | Positive regulation of mitochondrial membrane potential | Decreases phenotype | PMID:25482950 |
| GO:0010942 | Positive regulation of cell death | Increases phenotype | PMID:25482950 |
| GO:0016042 | Lipid catabolic process | Affects phenotype | PMID:33259821 |
| GO:0016049 | Cell growth | Decreases phenotype | PMID:18493934 |
| GO:0016477 | Cell migration | Decreases phenotype | PMID:33405312 |
| GO:0016570 | Histone modification | Affects phenotype | PMID:39922521 |
| GO:0018205 | Peptidyl-lysine modification | Affects phenotype | PMID:39922521 |
| GO:0019249 | Lactate biosynthetic process | Increases phenotype | PMID:31629899 |
| GO:0043065 | Positive regulation of apoptotic process | Increases phenotype | PMID:25482950 |
| GO:0044237 | Cellular metabolic process | Affects phenotype | PMID:31629899; PMID:33259821 |
| GO:0045820 | Negative regulation of glycolytic process | Increases phenotype | PMID:29653124 |
| GO:0046449 | Creatinine metabolic process | Affects phenotype | PMID:39922521 |
| GO:0060326 | Cell chemotaxis | Decreases phenotype | PMID:33405312 |
| GO:0072593 | Reactive oxygen species metabolic process | Affects phenotype | PMID:33259821 |
| GO:1902031 | Regulation of nadp metabolic process | Affects phenotype | PMID:25482950 |
| GO:1903428 | Positive regulation of reactive oxygen species biosynthetic process | Increases phenotype | PMID:25482950 |
| GO:2001170 | Negative regulation of atp biosynthetic process | Increases phenotype | PMID:29653124 |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.